Thomas Rasmussen

Thomas Gundelund Rasmussen holds an MSc in Systems Biology from the Technical University of Denmark and Stanford University. Thomas bring extensive experience in company creation and validating new technologies within drug development (immunology, gastroenterology, women's health and CNS) as well as industrial biotechnology (synthetic biology, meat protein replacements and alternative fuels).

Having lived and worked in China, Brazil, USA and Denmark he has been involved in bringing several products to market at at biotech leaders Novozymes & Chr. Hansen within biofuels, infant nutrition and synthetic biology, before leading the creation of the pharmaceutical division at Chr. Hansen. He then joined Flagship Pioneering company Kaleido Biosciences as VP of Business Development and Immuno Oncology. At Kaleido Biosciences he lead the collaboration with Prof Laurence Zitvogel at Gustave Roussy in Paris.

Before joining Forbion as Operating Partner and VectorY as interim head of BD, he co-founded clinical stage company Freya Biosciences with Laura Ensign at Johns Hopkins University among others, to pioneer the development of immunotherapies in womens health. Thomas is involved in several start-up incubators, including as co-founder of the dual degree M.Sc. in Bioentrepreneurship at Copenhagen Business School.